Genetic testing strategies for diagnosing hereditary cancer syndromes: From somatic testing to germline testing with illustrative <i>BRCA</i> cases

Purpose: Conventional indication-based germline BRCA1/2 testing (e.g., early-onset, triple-negative breast, or ovarian cancer) may miss some carriers.As tumor next-generation sequencing (NGS) becomes widely used for therapeutic guidance, it can identify variants suggestive of germline origin.This study describes our single-center experience with reflex germline testing triggered by tumor BRCA1/2 results to inform diagnostic approaches to hereditary cancer syndromes.Materials and Methods: We retrospectively reviewed eight consecutive patients with tumor NGS-detected BRCA1/2 variants who were referred for post-result counseling and confirmatory germline testing, identified from among 1,076 individuals counseled at Ewha Womans University Mokdong Hospital, Seoul, Korea, between 2018 and 2025.Results: Of eight patients with tumor BRCA1/2 variants, germline testing confirmed germline status in seven, while one was tumor-only.Two had high-grade serous ovarian carcinoma, where a germline origin was expected and confirmed.Two with bladder cancer-less typically BRCA-associated-had tumor variant allele frequencies of 46-50% and matched germline variants.One patient with endometrial and synchronous high-grade serous ovarian carcinoma had a BRCA1 variant on endometrial NGS, confirmed as germline.Another patient with liver metastasis from breast cancer harbored two BRCA2 variants (variant allele frequencies 49.1% and 10.5%); germline testing classified the 49.1% variant as germline and the 10.5% as somatic. Conclusion:Tumor-based NGS can reveal clinically actionable germline BRCA1/2 variants, especially in those who would otherwise fall outside current testing criteria Reflex germline testing following tumor sequencing may expand opportunities for early diagnosis of hereditary cancers.Standardized algorithms are needed to integrate tumor-based reflex testing into routine clinical practice.

Authors

Institutions

Publication Details

Journal
Journal of genetic medicine
Published
2025-12-30
DOI
https://doi.org/10.5734/jgm.2025.22.2.63
Primary Topic
BRCA gene mutations in cancer
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Genetic testing strategies for diagnosing hereditary cancer syndromes: From somatic testing to germline testing with illustrative BRCA cases

Boeun Yoo, Jungwon Huh, Min-Kyung So
Journal of genetic medicine
BRCA gene mutations in cancer
article

Genetic testing strategies for diagnosing hereditary cancer syndromes: From somatic testing to germline testing with illustrative BRCA cases

Boeun Yoo, Jungwon Huh, Min-Kyung So
article en

Abstract

Purpose: Conventional indication-based germline BRCA1/2 testing (e.g., early-onset, triple-negative breast, or ovarian cancer) may miss some carriers.As tumor next-generation sequencing (NGS) becomes widely used for therapeutic guidance, it can identify variants suggestive of germline origin.This study describes our single-center experience with reflex germline testing triggered by tumor BRCA1/2 results to inform diagnostic approaches to hereditary cancer syndromes.Materials and Methods: We retrospectively reviewed eight consecutive patients with tumor NGS-detected BRCA1/2 variants who were referred for post-result counseling and confirmatory germline testing, identified from among 1,076 individuals counseled at Ewha Womans University Mokdong Hospital, Seoul, Korea, between 2018 and 2025.Results: Of eight patients with tumor BRCA1/2 variants, germline testing confirmed germline status in seven, while one was tumor-only.Two had high-grade serous ovarian carcinoma, where a germline origin was expected and confirmed.Two with bladder cancer-less typically BRCA-associated-had tumor variant allele frequencies of 46-50% and matched germline variants.One patient with endometrial and synchronous high-grade serous ovarian carcinoma had a BRCA1 variant on endometrial NGS, confirmed as germline.Another patient with liver metastasis from breast cancer harbored two BRCA2 variants (variant allele frequencies 49.1% and 10.5%); germline testing classified the 49.1% variant as germline and the 10.5% as somatic. Conclusion:Tumor-based NGS can reveal clinically actionable germline BRCA1/2 variants, especially in those who would otherwise fall outside current testing criteria Reflex germline testing following tumor sequencing may expand opportunities for early diagnosis of hereditary cancers.Standardized algorithms are needed to integrate tumor-based reflex testing into routine clinical practice.

Journal of genetic medicineVol. 22(2)
Ewha Womans University (KR)
Openalex Percentile: Top 24%
BRCA gene mutations in cancer
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Genetic testing strategies for diagnosing hereditary cancer syndromes: From somatic testing to germline testing with illustrative <i>BRCA</i> cases — Boeun Yoo, Jungwon Huh, et al. · Journal of genetic medicine (2025) | TGRS Research Map | TGRS